Abstract: A mesoporous polymeric membrane for use as an ionically-conductive inter-electrode separator in a rechargeable battery cell contains a like distribution of mesopore voids throughout a membrane matrix. The porous membrane is capable of absorbing significant amounts of electrolyte solution to provide suitable ionic conductivity for use in rechargeable battery cells. The addition of inert particulate filler to the coating composition provides further strength in the body of the membrane and provides particulate support within the membrane mesopores which prevents collapse of the voids at cell fabrication laminating temperatures and thus maintains electrolyte absorption capability.

Abstract: The invention provides novel lithium-mixed metal materials which, upon electrochemical interaction, release lithium ions, and are capable of reversibly cycling lithium ions. The invention provides a rechargeable lithium battery which comprises an electrode formed from the novel lithium-mixed metal materials. Methods for making the novel lithium-mixed metal materials and methods for using such lithium-mixed metal materials in electrochemical cells are also provided. The lithium-mixed metal materials comprise lithium and at least one other metal besides lithium. Preferred materials are lithium-mixed metal phosphates which contain lithium and two other metals besides lithium.

Abstract: A battery package assembly comprises a package having an interior volume sealingly containing at least one electrochemical cell therein, and opposite polarity electrical connectors adapted to connect said at least one electrochemical cell to an external load. At least one of the opposite polarity electrical connectors is adapted to automatically shut down the battery in response to a sufficient increase in internal pressure within the battery package.

Abstract: Anodes, cathodes, and/or solid electrolytes (or separator layers) of an electrochemical cell can be fabricated from aqueous compositions containing monomers and/or polymers. In one formulation, the aqueous composition contains binding materials that are polymerized and crosslinked. In a second formulation, the composition is a latex having as aqueous phase and a solid polymer phase. Upon removal of water, the compositions provide a polymeric structure suitable for use as an electrode or solid electrolyte.

Abstract: A method of fabricating electrochemical cells and batteries wherein the successive anode and cathode layers are separated by a polymeric electrolyte layer having a protruding polymer edge around its perimeter which reduces the likelihood of inadvertent contact between the anode and cathode current collectors is provided. The polymer edge functions as a non-conducting physical barrier positioned between adjacent current collectors. An apparatus for preparing electrochemical cells is also disclosed.

Abstract: In one embodiment, the invention provides a novel composition which is stabilized against decomposition when used as an active material for an electrochemical cell. The active material of the present invention comprises particles of spinel lithium manganese oxide (LMO) enriched with lithium by a decomposition product of lithium hydroxide forming a part of each of the LMO particles. The spinel LMO product formed by the decomposition of lithium hydroxide in the presence of the LMO is characterized by a reduced surface area and increased capacity retention (reduced capacity fading) as compared to the initial, non-treated, non-enriched spinel. In another aspect, the treated spinel LMO product is combined with lithium carbonate in a cathode mixture.

Abstract: A method for activating electrochemical cells including the steps of sealing the electrochemical cells in a container with an activating electrolyte solvent and salt, treatment steps, such as the application of compression and decompression cycles to the container, for providing good distribution of the electrolyte within the electrochemical cells.

Abstract: The present invention is directed to low molecular weight mimics of superoxide dismutase (SOD) represented by the formula: ##STR1## wherein R, R', R.sub.1, R'.sub.1, R.sub.2, R'.sub.2, R.sub.3, R'.sub.3, R.sub.4, R'.sub.4, R.sub.5, R'.sub.5, R.sub.6, R'.sub.6, R.sub.7, R'.sub.7, R.sub.8, R'.sub.8, R.sub.9, and R'.sub.9 and X, Y, Z and n are as defined herein, useful as therapeutic agents for inflammatory disease states and disorders, ischemic/reperfusion injury, stroke, atherosclerosis, hypertension and all other conditions of oxidant-induced tissue damage or injury.

Abstract: This invention relates to 2-?(1H-benzimidazol-2-ylsulfinyl)methyl!benzenamines that are useful in the treatment and prevention of ulcers.

Abstract: A drug delivery system adapted to release an effective amount of a drug at pH values of about 1 to 7 without releasing a significant amount of the drug at pH values of about 7 and above, the system comprising a polymeric material and a drug covalently bonded to the polymeric material through a pH sensitive covalent bond capable of being cleaved in the pH range of 1 to about 7.

Abstract: This invention herein relates to compounds having the following formula ##STR1## or a pharmaceutically acceptable salt thereof which are useful in the inhibition of platelet aggregation, to pharmaceutical compositions containing the compound and to a method of inhibiting platelet aggregation in mammals by administering such compounds and compositions.

Abstract: The present invention relates to a class of compounds represented by the Formula I ##STR1## or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the .alpha..sub.v .beta..sub.3 integrin.

Abstract: The present invention relates to controlled release dosage forms composed of a naproxen layer which contains a delayed release granulate of naproxen compressed with an immediate release granulate of naproxen and an immediate release naproxen sodium layer compressed with the naproxen layer, designed to promptly exert a therapeutic effect while also maintaining the therapeutic blood concentration for a prolonged duration of 24 hours.

Abstract: The present invention relates to a novel process for the preparation of N-heterocyclealkanamide derivatives having the following formula: ##STR1## which comprises reacting 1-(2-chloroethyl)piperidine with 2-chlorobenzeneacetonitrile to give (.+-.)-.alpha.-(2-chlorophenyl)-1-piperidinebutanenitrile; alkylating the piperidenebutanenitrile to give (.+-.)-.alpha.-(2-chlorophenyl)-.alpha.-(2,2-dimethoxyethyl)piperidine-1-b utanenitrile; hydrolyzing the resulting alkylated piperidinebutanenitrile to give (.+-.)-.alpha.-(2-chlorophenyl)-.alpha.-(2-oxoethyl)piperidine-1-butanenit rile; reacting the resulting piperidinebutanenitrile with isopropylamine to form (.+-.)-.alpha.-(2-chlorophenyl)-.alpha.-?2-?(1-methylethyl)imino!ethyl!pip eridine-1-butanenitrile; reducing the resulting imine to form (.+-.)-.alpha.-(2-chlorophenyl)-.alpha.-?2-?(1-methylethyl)amino!ethyl!-pi peridine-1-butanenitrile; acetylating the resulting amine to form (.+-.

Abstract: This invention relates to compounds having the following formula ##STR1## or a pharmaceutically acceptable salt thereof which are useful in the inhibition of platelet aggregation, to pharmaceutical compositions of such phenylamidines derivatives, and to a method of inhibiting platelet aggregation in mammals by administering such compounds and compositions.

Abstract: A process for preparing a substituted polyazamacrocycle is provided which comprises contacting a diamine or triamine and a dicarboxylic acid or ester or anhydride thereof in the presence of a suitable base and a suitable solvent to produce the substituted polyazamacrocycle provided that when an ester of said dicarboxylic acid is used, said suitable base is optional, and when said dicarboxylic acid or an anhydride of said dicarboxylic acid is used, the reaction mixture further comprises a suitable coupling agent.

Abstract: A process for the preparation of a .gamma.-lactone of the formula ##STR1## which can be used to produce a single enantiomer of aminoazanoradamantane which is coupled to aromatic acid moieties to produce compounds useful as 5-HT agonists or antagonists.

Abstract: Novel N-Acyl Beta Amino Acid derivatives of the formula ##STR1## are provided which inhibit platelet aggregation. This invention also pertains to pharmaceutical compositions and methods of using such derivatives.

Abstract: The invention relates to platelet aggregation inhibitors which are substituted beta amino acid derivatives of the formula: ##STR1## wherein Z, A, Z', Z", W, q, R.sup.1 and R.sup.2 are as defined in the specification.

Abstract: A pharmaceutical composition including a core of an NSAID selected from diclofenac and piroxicam which core is surrounded by a mantle coating of a prostaglandin, wherein an intermediate coating can be present between the NSAID core and prostaglandin mantle coating.